Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.